CN115590892A - Female private probiotic bacteria inhibiting powder containing probiotic bacteria composite powder and preparation method - Google Patents
Female private probiotic bacteria inhibiting powder containing probiotic bacteria composite powder and preparation method Download PDFInfo
- Publication number
- CN115590892A CN115590892A CN202211265940.4A CN202211265940A CN115590892A CN 115590892 A CN115590892 A CN 115590892A CN 202211265940 A CN202211265940 A CN 202211265940A CN 115590892 A CN115590892 A CN 115590892A
- Authority
- CN
- China
- Prior art keywords
- powder
- probiotic
- parts
- lactobacillus
- composite powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a female private probiotic bacteriostatic powder containing probiotic composite powder and a preparation method thereof, wherein the female private probiotic bacteriostatic powder containing probiotic composite powder specifically comprises the following components: 20-40 parts of probiotic composite powder, 1-3 parts of D-mannitol, 1-3 parts of fructo-oligosaccharide, 0.1-0.3 part of microcrystalline cellulose and 0.03-0.07 part of vitamin, wherein the probiotic composite powder comprises nisi powder, inactivated lactobacillus powder, bifidobacterium adolescentis powder, lactobacillus acidophilus powder, lactobacillus rhamnosus powder, lactobacillus plantarum powder and lactobacillus salivarius powder. The invention relates to the technical field of antibacterial powder, and particularly provides female private probiotic antibacterial powder containing probiotic composite powder, which can effectively keep vaginal nursing balance, has mild drug effect and no drug resistance, and does not influence beneficial floras such as vaginal lactobacilli and the like, and a preparation method thereof.
Description
Technical Field
The invention relates to the technical field of antibacterial powder, in particular to female private probiotic antibacterial powder containing probiotic composite powder and a preparation method thereof.
Background
Vaginitis is a common disease of obstetrics and gynecology department, married women suffer from vaginitis for at least 1-2 times in the lifetime, and pregnant and lying-in women suffer from vaginitis, which can affect the result of pregnancy and the disease course after delivery. Generally, the vagina has some resident flora such as B-type hemolytic streptococcus, candida albicans and the like, and when the body resistance is low, the vaginal mucosa is injured or the acidity in the vagina is changed, the virulence of the bacteria is increased, and the bacteria become pathogenic bacteria to cause vaginitis to happen. For example, the glycogen content of vaginal epithelial cells of a pregnant woman is increased, the acidity of the vagina is enhanced, the renal threshold is reduced, the sugar content in urine is increased, and the growth and the reproduction of candida albicans are promoted. Clinically, vaginitis is classified into nonspecific, fungal, bacterial, viral and protozoal vaginitis, depending on the etiology of the inflammatory disease of the vagina.
The current major treatment for the disease is by antibiotic or antiseptic treatment, killing all vaginal bacteria thoroughly to clean the vagina. The vagina after treatment often needs a long time for self-repair, and more serious people can lose the self-regulation capability of the vagina due to improper treatment. The existing antibiotics and bactericides can kill probiotics while killing harmful bacteria, so that the environment in the vagina is disrupted after the probiotics die.
Probiotics (Probiotics) is a kind of active microorganisms beneficial to a host, and is a general term for active beneficial microorganisms which are planted in the intestinal tract and reproductive system of a human body or an animal and can produce exact health effects so as to improve the microbial ecological balance of the host and play beneficial roles. It acts primarily by improving the balance of the host's intestinal microflora. It has effects in improving intestinal flora structure, inhibiting pathogenic bacteria, generating nutrient substances, enhancing immunity, eliminating carcinogenic factors, reducing cholesterol and blood pressure, and improving lactose digestibility. The probiotics with the bacteriostatic function is beneficial to improving a flora system and maintaining the health balance of the environment in the vagina while killing harmful bacteria.
Disclosure of Invention
Aiming at the situation, the invention provides the female private probiotic bacteria inhibiting powder containing the probiotic bacteria composite powder, which can effectively keep the vaginal nursing balance, has mild medicinal effect and no drug resistance, and does not influence beneficial flora such as vaginal lactobacilli and the like, and the preparation method thereof.
The invention provides the following technical scheme: the invention provides a female private probiotic bacteria inhibiting powder containing probiotic composite powder, which specifically comprises the following components: 20-40 parts of probiotic composite powder, 1-3 parts of D-mannitol, 1-3 parts of fructo-oligosaccharide, 0.1-0.3 part of microcrystalline cellulose and 0.03-0.07 part of vitamin, wherein the probiotic composite powder comprises nisia powder, inactivated lactobacillus powder, bifidobacterium adolescentis powder, lactobacillus acidophilus powder, lactobacillus rhamnosus powder, lactobacillus plantarum powder and lactobacillus salivarius powder.
Preferably, the female intimate probiotic bacteriostatic powder containing the probiotic composite powder specifically comprises the following components: 25-35 parts of probiotic composite powder, 1.5-2.5 parts of D-mannitol, 1.5-2.5 parts of fructo-oligosaccharide, 0.15-0.25 part of microcrystalline cellulose and 0.04-0.06 part of vitamin, wherein the probiotic composite powder comprises nisi powder, inactivated lactobacillus powder, bifidobacterium adolescentis powder, lactobacillus acidophilus powder, lactobacillus rhamnosus powder, lactobacillus plantarum powder and lactobacillus salivarius powder.
Preferably, the female intimate probiotic bacteriostatic powder containing the probiotic composite powder specifically comprises the following components: 30 parts of probiotic composite powder, 2.0 parts of D-mannitol, 2.0 parts of fructo-oligosaccharide, 0.20 part of microcrystalline cellulose and 0.05 part of vitamin, wherein the probiotic composite powder comprises streptococcus lactis powder, inactivated lactobacillus powder, bifidobacterium adolescentis powder, lactobacillus acidophilus powder, lactobacillus rhamnosus powder, lactobacillus plantarum powder and lactobacillus salivarius powder.
Further, the probiotic composite powder comprises 4-8 parts of streptococcus lactis powder, 3-7 parts of inactivated lactobacillus powder, 3-7 parts of bifidobacterium adolescentis powder, 3-5 parts of lactobacillus acidophilus powder, 3-5 parts of lactobacillus rhamnosus powder, 2-4 parts of lactobacillus plantarum powder and 2-4 parts of lactobacillus salivarius powder.
The invention provides a preparation method of female private probiotic bacteria inhibiting powder containing probiotic composite powder, which specifically comprises the following steps:
(1) Uniformly mixing and homogenizing nisin powder, inactivated nisin powder, bifidobacterium adolescentis powder, lactobacillus acidophilus powder, lactobacillus rhamnosus powder, lactobacillus plantarum powder and lactobacillus salivarius powder in corresponding parts by weight to obtain probiotic composite powder;
(2) D-mannitol, fructo-oligosaccharide, microcrystalline cellulose, vitamins and the probiotic composite powder are uniformly mixed and dried to obtain the female intimate probiotic bacteriostatic powder containing the probiotic composite powder.
The invention adopting the structure has the following beneficial effects: according to the female private probiotic bacteria inhibiting powder containing the probiotic composite powder and the preparation method, flora in the vagina is regulated by adopting a mode of combining multiple beneficial probiotics, namely, microorganisms form a mutually coordinated microecosystem in the vagina, so that the health of the vagina is kept; meanwhile, the D-mannitol, the fructo-oligosaccharide and the vitamins provide nutrition for the composite probiotics and promote the growth of the composite probiotics, so that the quantity of the composite probiotics is increased, and the requirement of a vaginal micro-ecosystem is met.
Detailed Description
The technical solutions of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments; all other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
The female private probiotic bacterium inhibiting powder containing the probiotic compound powder specifically comprises the following components: the probiotic compound powder comprises 30 parts of probiotic compound powder, 2.0 parts of D-mannitol, 2.0 parts of fructo-oligosaccharide, 0.20 part of microcrystalline cellulose and 0.05 part of vitamin, wherein the probiotic compound powder comprises 6 parts of streptococcus lactis powder, 5 parts of inactivated lactobacillus powder, 5 parts of bifidobacterium adolescentis powder, 4 parts of lactobacillus acidophilus powder, 4 parts of lactobacillus rhamnosus powder, 3 parts of lactobacillus plantarum powder and 3 parts of lactobacillus salivarius powder.
The invention provides a preparation method of female private probiotic bacteria inhibiting powder containing probiotic composite powder, which specifically comprises the following steps:
(1) Uniformly mixing and homogenizing nisin powder, inactivated nisin powder, bifidobacterium adolescentis powder, lactobacillus acidophilus powder, lactobacillus rhamnosus powder, lactobacillus plantarum powder and lactobacillus salivarius powder in corresponding parts by weight to obtain probiotic composite powder;
(2) D-mannitol, fructo-oligosaccharide, microcrystalline cellulose, vitamins and the probiotic composite powder are uniformly mixed and dried to obtain the female intimate probiotic bacteriostatic powder containing the probiotic composite powder.
Example 2
The female private probiotic bacterium inhibiting powder containing the probiotic compound powder specifically comprises the following components: 20 parts of probiotic composite powder, 1.0 part of D-mannitol, 1.0 part of fructo-oligosaccharide, 0.1 part of microcrystalline cellulose and 0.03 part of vitamin, wherein the probiotic composite powder comprises 4 parts of streptococcus lactis powder, 3 parts of inactivated lactobacillus powder, 3 parts of bifidobacterium adolescentis powder, 3 parts of lactobacillus acidophilus powder, 3 parts of lactobacillus rhamnosus powder, 2 parts of lactobacillus plantarum powder and 2 parts of lactobacillus salivarius powder.
The invention provides a preparation method of female private probiotic bacteria-inhibiting powder containing probiotic composite powder, which specifically comprises the following steps:
(1) Uniformly mixing and homogenizing nisin powder, inactivated nisin powder, bifidobacterium adolescentis powder, lactobacillus acidophilus powder, lactobacillus rhamnosus powder, lactobacillus plantarum powder and lactobacillus salivarius powder in corresponding parts by weight to obtain probiotic composite powder;
(2) D-mannitol, fructo-oligosaccharide, microcrystalline cellulose, vitamins and the probiotic composite powder are uniformly mixed and dried to obtain the female intimate probiotic bacteriostatic powder containing the probiotic composite powder.
Example 3
The female private probiotic antibacterial powder containing the probiotic composite powder specifically comprises the following components: 40 parts of probiotic composite powder, 3 parts of D-mannitol, 3 parts of fructo-oligosaccharide, 0.3 part of microcrystalline cellulose and 0.07 part of vitamin, wherein the probiotic composite powder comprises 8 parts of streptococcus lactis powder, 7 parts of inactivated lactobacillus powder, 7 parts of bifidobacterium adolescentis powder, 5 parts of lactobacillus acidophilus powder, 5 parts of lactobacillus rhamnosus powder, 4 parts of lactobacillus plantarum powder and 4 parts of lactobacillus salivarius powder.
The invention provides a preparation method of female private probiotic bacteria-inhibiting powder containing probiotic composite powder, which specifically comprises the following steps:
(1) Uniformly mixing and homogenizing nisin powder, inactivated nisin powder, bifidobacterium adolescentis powder, lactobacillus acidophilus powder, lactobacillus rhamnosus powder, lactobacillus plantarum powder and lactobacillus salivarius powder in corresponding parts by weight to obtain probiotic composite powder;
(2) D-mannitol, fructo-oligosaccharide, microcrystalline cellulose, vitamins and the probiotic composite powder are uniformly mixed and dried to obtain the female intimate probiotic bacteriostatic powder containing the probiotic composite powder.
And (3) performance testing:
1. and (3) pH value determination: the determination is carried out according to the Disinfection technical Specification 2002 edition 2.2.1.4 of the Ministry of health
The test environment temperature is 20.1 ℃; relative humidity 57%, sample concentration 1:20 are dissolved.
The results are as follows:
| sample number | pH value |
| 1 | 5.11 |
| 2 | 5.11 |
The pH value of the female intimate probiotic bacteriostatic powder containing the probiotic composite powder provided by the invention is measured to be acidic, so that the acidic environment of the female vagina can be better protected.
2. Lead, arsenic, mercury content: according to Chapter IV of technical Specification for safety of cosmetics (2015 edition)
Detecting the environment: the temperature was 21 ℃ and the relative humidity was 50%.
The results were as follows:
| detecting items | Detection limit | The result of the detection |
| Lead (II) | 1.5mg/kg | Not detected out |
| Arsenic (As) | 0.01mg/kg | Undetected |
| Mercury | 0.002mg/kg | Not detected out |
The detection result shows that lead, arsenic and mercury are not detected in the female intimate probiotic bacteria inhibiting powder containing the probiotic composite powder, and the use safety is higher.
3. And (3) bacteriostatic rate test: according to appendix C of 'hygienic Standard for Disposable sanitary articles' GB15979-2002
Dripping 10 μ L of the bacterial suspension into the sample sheet, oven drying, placing into 5ml of sample solution, acting for 2min, adding the carrier for infecting bacteria into 5ml of PBS, mixing, shaking, absorbing 1ml of sample solution, inoculating, culturing, and counting viable bacteria.
Test temperature: 20 +/-1 ℃; the test was repeated 3 times.
The results are as follows:
note: the negative control group was grown aseptically.
Through inspection, the female private probiotic bacteriostatic powder containing the probiotic composite powder provided by the invention has the bacteriostatic rate of more than 90% on staphylococcus aureus, escherichia coli and candida albicans after 2min of action.
4. And (3) detecting microbial contamination: appendix B according to GB15979-2002
Detection conditions are as follows: ambient temperature 22.3 ℃ and relative humidity 50%.
The results were as follows:
| detecting the index | Standard value of | Measured value |
| Total bacterial colony count (cfu/ml) | ≤200 | ＜20 |
| Large intestineBacterial flora | Cannot be detected | Not detected out |
| Staphylococcus aureus | Cannot be detected | Not detected out |
| Pseudomonas aeruginosa | Cannot be detected | Undetected |
| Hemolytic streptococcus | Cannot be detected | Not detected out |
| Total fungal colony count (cfu/ml) | ≤100 | ＜20 |
5. Multiple vaginal mucosa irritation test
(I) apparatus
1. And (3) testing a sample: the supersaturated solution is prepared by adding 20ml of water into 1 tablet, and the supersaturated solution is taken as a test sample to be directly used. The control group was saline.
2. Experimental animals:
the healthy Japanese big ear white rabbit is 6, common grade, the weight is 2.34-2.39 kg.
3. The test conditions are as follows:
ambient temperature: 20.8-22.8 ℃, relative humidity: 41.1 to 69.9 percent.
(II) method
1. The detection basis is as follows: disinfection technical Specification of Ministry of health (2002 edition) 2.3.5 vaginal mucosa irritation test
2. The test method comprises the following steps: in the test, 3 female Japanese big-ear white rabbits were used in total, and 3 animals were used in the infected group. Control group, 3 animals. The vaginal orifice of the animal was examined for the presence of secretions, congestion, edema and other lesions prior to testing. Such as inflammation or (and) injury, is discarded. The infected group was given 2mL of the sample stock vaginally. And (3) killing the animals 24h after the infection by using carbon dioxide, taking the complete vagina, longitudinally splitting the vagina, and visually observing whether congestion, edema and other manifestations exist. Then fixing for more than 24h by using 10% formalin solution, selecting tissues at two ends and 3 parts in the center of the vagina for tissue section, and performing pathological examination and stimulation response scoring.
3. Sample administration route and method: the rabbit is fixed on a rabbit fixing frame, and the perineum and the vaginal opening are exposed. The catheter was wetted with the test sample and gently inserted into the vagina (4-5 cm) and 2mL of the sample was slowly injected with a syringe and the catheter withdrawn to complete the contamination.
(III) results:
after the female private probiotic antibacterial powder containing the probiotic composite powder provided by the invention is repeatedly given to the vagina of a rabbit, the vaginal tissue of infected animals has no macroscopic irritation reaction. Histopathological examination results show that there was no significant difference between the infected group and the control group, and the specific stimulation score results are shown in the following table.
Test results show that after the female private probiotic bacteria inhibiting powder containing the probiotic composite powder is repeatedly given to the vagina of the rabbit, the vagina tissues of 3 animals in a contaminated group have no obvious stimulation reaction. The histopathological examination result shows that the scores of 3 animals in the infected group and the control group have no obvious difference, and the final vaginal mucosa irritation index of the test sample is 0.67. The irritation is judged to be no according to the multiple vaginal mucosa stimulation intensity of a test sample in the disinfection technical specification (2002 edition) -2.3.5 vaginal mucosa stimulation test, and meets the requirements of the disinfection technical specification (2002 edition).
It is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (5)
1. The female private probiotic bacterium inhibiting powder containing the probiotic compound powder is characterized by specifically comprising the following components: 20-40 parts of probiotic composite powder, 1-3 parts of D-mannitol, 1-3 parts of fructo-oligosaccharide, 0.1-0.3 part of microcrystalline cellulose and 0.03-0.07 part of vitamin, wherein the probiotic composite powder comprises nisia powder, inactivated lactobacillus powder, bifidobacterium adolescentis powder, lactobacillus acidophilus powder, lactobacillus rhamnosus powder, lactobacillus plantarum powder and lactobacillus salivarius powder.
2. The female intimate probiotic bacteriostatic powder containing the probiotic composite powder according to claim 1, which is characterized by specifically comprising the following components: 25-35 parts of probiotic composite powder, 1.5-2.5 parts of D-mannitol, 1.5-2.5 parts of fructo-oligosaccharide, 0.15-0.25 part of microcrystalline cellulose and 0.04-0.06 part of vitamin, wherein the probiotic composite powder comprises nisi powder, inactivated lactobacillus powder, bifidobacterium adolescentis powder, lactobacillus acidophilus powder, lactobacillus rhamnosus powder, lactobacillus plantarum powder and lactobacillus salivarius powder.
3. The female intimate probiotic bacteriostatic powder containing the probiotic composite powder according to claim 1, which is characterized by specifically comprising the following components: 30 parts of probiotic composite powder, 2.0 parts of D-mannitol, 2.0 parts of fructo-oligosaccharide, 0.20 part of microcrystalline cellulose and 0.05 part of vitamin, wherein the probiotic composite powder comprises streptococcus lactis powder, inactivated lactobacillus powder, bifidobacterium adolescentis powder, lactobacillus acidophilus powder, lactobacillus rhamnosus powder, lactobacillus plantarum powder and lactobacillus salivarius powder.
4. The female intimate probiotic bacteria inhibiting powder containing probiotic bacteria composite powder according to any one of claims 1 to 3, characterized in that the probiotic bacteria composite powder comprises 4 to 8 parts of nisia powder, 3 to 7 parts of inactivated nisia powder, 3 to 7 parts of bifidobacterium adolescentis powder, 3 to 5 parts of lactobacillus acidophilus powder, 3 to 5 parts of lactobacillus rhamnosus powder, 2 to 4 parts of lactobacillus plantarum powder and 2 to 4 parts of lactobacillus salivarius powder.
5. The preparation method of the female intimate probiotic bacteriostatic powder containing the probiotic composite powder according to claim 4, which is characterized by comprising the following steps:
(1) Uniformly mixing and homogenizing nisin powder, inactivated nisin powder, bifidobacterium adolescentis powder, lactobacillus acidophilus powder, lactobacillus rhamnosus powder, lactobacillus plantarum powder and lactobacillus salivarius powder in corresponding parts by weight to obtain probiotic composite powder;
(2) D-mannitol, fructo-oligosaccharide, microcrystalline cellulose, vitamins and the probiotic composite powder are uniformly mixed and dried to obtain the female intimate probiotic bacteriostatic powder containing the probiotic composite powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211265940.4A CN115590892A (en) | 2022-10-17 | 2022-10-17 | Female private probiotic bacteria inhibiting powder containing probiotic bacteria composite powder and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211265940.4A CN115590892A (en) | 2022-10-17 | 2022-10-17 | Female private probiotic bacteria inhibiting powder containing probiotic bacteria composite powder and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115590892A true CN115590892A (en) | 2023-01-13 |
Family
ID=84847868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211265940.4A Pending CN115590892A (en) | 2022-10-17 | 2022-10-17 | Female private probiotic bacteria inhibiting powder containing probiotic bacteria composite powder and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115590892A (en) |
-
2022
- 2022-10-17 CN CN202211265940.4A patent/CN115590892A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8765819B2 (en) | Composition comprising benzoic acid in combination with organic acid preservatives as active ingredients and the use thereof | |
| KR101133723B1 (en) | Composition comprising salt and sugar for protecting and treating vaginosis disease and the use thereof | |
| US6156320A (en) | Fermented milk nutraceuticals | |
| BRPI0314060B1 (en) | a composition comprising lactobacillus fermentum variant or variant component and uses of the lactobacillus fermentum variant or variant component and composition | |
| JP2016533744A (en) | Lactobacillus strains as probiotics | |
| US6358521B1 (en) | Fermented milk nutraceuticals | |
| CN111084831A (en) | Bacteriostatic composition for inhibiting vaginal pathogenic bacteria and application thereof | |
| WO2018100533A1 (en) | Urogenital medical device formulation based on suitable biochemical compositions for the stabilization of the acidity and the redox state of the vaginal fluid | |
| CN108295096B (en) | Application of bacterial strain in preparation for preventing and treating mycotic and bacterial vaginosis | |
| CN109985069B (en) | Probiotic compositions and uses thereof | |
| CN113278548A (en) | Lactobacillus crispatus and application thereof in producing products for improving human vaginal environment | |
| Mohanty et al. | Comparison of 2 g single dose of metronidazole, nimorazole and tinidazole in the treatment of vaginitis associated with Gardnerella vaginalis | |
| Hooton et al. | Association of acute cystitis with the stage of the menstrual cycle in young women | |
| CN115590892A (en) | Female private probiotic bacteria inhibiting powder containing probiotic bacteria composite powder and preparation method | |
| TW201316996A (en) | A novel strain of Lactobacillus and its use in inhibition of vaginitis | |
| Ekgren et al. | Comparison of tinidazole given as a single dose and on 2 consecutive days for the treatment of nonspecific bacterial vaginosis | |
| CN115517367A (en) | Application of lactobacillus paracasei SMN-LBK in preparation of product for promoting intestinal health | |
| CN105079000B (en) | A kind of composition and its application, preparation | |
| CN113308405A (en) | Novel double-probiotic synergistic composite inoculant and application thereof | |
| CN109045044B (en) | Compound medicament and preparation method and application thereof | |
| EP3941499A1 (en) | A composition for competitive inhibition of pathogens and restoration of microbial ecological balance | |
| KR102014810B1 (en) | Composition for prevention and treatment of vaginitis | |
| CN111437282A (en) | Application of 2' -fucosyllactose in reducing in vivo colonization of escherichia coli O157 | |
| CN115590891A (en) | Probiotic freeze-dried active bacteria bacteriostatic tablet for gynecology and preparation method thereof | |
| RU2322996C2 (en) | Wound-healing biopreparation as gel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |